拉米夫定初始联合阿德福韦酯治疗乙型肝炎失代偿期肝硬化疗效观察

目的：观察拉米夫定初始联合阿德福韦酯治疗乙型肝炎失代偿期肝硬化的疗效和安全性。方法：36例伴有HBV复制的失代偿期肝硬化患者,随机均分为拉米夫定初始联合阿德福韦治疗组和对照组,对照组单用阿德福韦,每3个月评价1次,疗程12个月。结果：肝功能指标和Child-Pugh评分治疗6个月时,治疗组显著优于对照组,疗程结束时差异无统计学意义;HBVDNA阴转率,于治疗3、6、9、12个月,治疗组均显著优于对照组,未发生耐药变异。结论：拉米夫定初始联合阿德福韦治疗HBV所致失代偿期肝硬化,可快速抑制病毒复制和改善肝功能,安全性、耐受性好,优于单用阿德福韦酯组。

Clinical study of Lamivudine combined with Adforvir Dipivoxil in the treatment of chronic hepatitis B patients with cirrhosis in their decompensation period

Objective：To observe the effecacy and safety of Lanivudine（LAM） combined with Adforvir Dipivoxil（ADV） in the treatment of chronic hepatitis B patients with cirrhosis in their decompensation period. Methods：36 cases with decompensation liver cirrhosis with HBV duplicate were randomly divided into the treated group who were given LAM combined with ADV and control group who were only given ADV. The course of the treatment lasted 12 months and be evaluated every three months. Results：For the index of liver function and Child-Pugh score treatment after 6 months,the effects in treated group were superior to those in control group,there was no statistical significance at the end of the treatment. The negative rate of HBV DNA after 3,6,9 and 12 months,the effects in treated group were better than that in the control group,there was no drug resistance. Conclusion：LAM combined with ADV in the treatment of HBV result in patients with decompensation cirrhosis,can restraining virus to duplicate quickly,improve liver function,have a favorable safety and tolerability profile,the effects was superior to those in control group.